. . "19220"^^ . . . "*P\u0159\u00ED\u010Dinou ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F p\u0159i l\u00E9\u010Db\u011B warfarinem je jeho n\u00EDzk\u00FD terapeutick\u00FD index a z\u00E1rove\u0148 zna\u010Dn\u00E1 interindividu\u00E1ln\u00ED variabilita d\u00E1vky l\u00E9ku. V sou\u010Dasnosti je v\u0161ak mo\u017En\u00E9 vyu\u017E\u00EDt genetick\u00E9ho testov\u00E1n\u00ED, kter\u00E9 umo\u017E\u0148uje ur\u010Dit d\u00E1vku warfarinu na z\u00E1klad\u011B genetick\u00E9 v\u00FDbavy dan\u00E9ho jedince. Proto c\u00EDlem projektu je diagnostick\u00FD produkt (ve variant\u011B PCR kit a HRMA kit) pro detekci genetick\u00E9ho profilu pacienta, podle kter\u00E9ho m\u016F\u017Ee b\u00FDt vypo\u010Dtena denn\u00ED d\u00E1vka warfarinu. Ve spojen\u00ED s unik\u00E1tn\u00ED v\u00FDpo\u010Detn\u00ED aplikac\u00ED p\u0159edstavuje velk\u00FD p\u0159\u00EDnos pro zv\u00FD\u0161en\u00ED bezpe\u010Dnosti pacienta, ve sn\u00ED\u017Een\u00ED rizikovosti aplikace a v ekonomick\u00FDch parametrech l\u00E9\u010Dby. Spole\u010Dn\u00FDm c\u00EDlem firem GeneProof, a.s., Genex CZ, s.r.o. a Nemocnice na Homolce je prototyp produktu, kter\u00FD se dob\u0159e uplatn\u00ED na trhu, zajist\u00ED stabilitu a r\u016Fst jmenovan\u00FDch firem a p\u0159isp\u011Bje k rozvoji spolupr\u00E1ce na VaV mezi soukrom\u00FDm a ve\u0159ejn\u00FDm sektorem."@cs . . . "2009-04-01+01:00"^^ . "0"^^ . "6"^^ . "*Development of DNA-based diagnostic kit for therapeutic warfarin dose evaluation"@en . . "1"^^ . "6"^^ . "*The cause of unexpected bleeding in warfarin treatment is its low therapeutic index and gross inter-individual dosing. Nowadays it is possible to adjust the individual dosage by genetic testing of polymorphic variability in patients. Thus the aim of the project is to develop a diagnostic product (in variant PCR kit anf HRM kit) for genetic profiling of patients and the calculation of dosage based on the genetic profile. This approach provides a benefit in lowering the risk for patients in unexpected effects. The common goal of GeneProof, Genex and Hospital Na Homolce is to develop a product prototype, with optimal market introduction and development of innovative cooperation between private and public sector"@en . . . "1"^^ . "*V\u00FDvoj farmakogenetick\u00E9ho diagnostick\u00E9ho kitu pro ur\u010Den\u00ED d\u00E1vky warfarinu"@cs . . "2012-12-31+01:00"^^ . . . "coagulation therapy; warfarin; risk of unexpected bleeding; Cyp2C9; VKORC1; dosage adjustment"@en . "12881"^^ .